Herpes zoster: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(New page: ==Prevention== The Centers for Disease Control recommends the zoster vaccination for adults aged at least 60 years:<ref>{{cite web |url=http://www.cdc.gov/od/oc/media/pressrel/r061026....)
 
imported>Robert Badgett
Line 1: Line 1:
==Prevention==
==Prevention==
The [[Centers for Disease Control]] recommends the zoster vaccination for adults aged at least 60 years:<ref>{{cite web |url=http://www.cdc.gov/od/oc/media/pressrel/r061026.htm |author=Centers for Disease Control and Prevention|title=CDC Media Relations Press Release - October 26, 2006 |accessdate=2007-10-22 |format= |work=|year=2006}}</ref>
The [[Centers for Disease Control]] recommends the zoster vaccination (Zostavax - which is different than the pediatric vaccine Variva) for adults aged at least 60 years:<ref>{{cite web |url=http://www.cdc.gov/od/oc/media/pressrel/r061026.htm |author=Centers for Disease Control and Prevention|title=CDC Media Relations Press Release - October 26, 2006 |accessdate=2007-10-22 |format= |work=|year=2006}}</ref> Contraindications include:<ref>{{cite web |url=http://www.fda.gov/cber/products/zosmer052506qa.htm |title=CBER - Zoster Vaccine, Live, (Oka/Merck), Zostavax Questions & Answers |accessdate=2007-10-22 |format= |work=}}</ref>
* allergic to neomycin, or any component of the vaccine
* immuncompromise due to radiation, corticosteroids, or conditions such as AIDS and cancers.
* pregnancy
* people who are in close contact with pregnant women who have not had chickenpox probably not have vaccine


A [[randomized controlled trial]] of a vaccine for adults aged at least 60 years reduced the incidence of zoster from 3.3% to 1.6%; approximately 60 people would have to take the vaccine to prevent one case of shingles ([[number needed to treat]]=59).<ref name="pmid15930418">{{cite journal |author=Oxman MN, Levin MJ, Johnson GR, ''et al'' |title=A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults |journal=N. Engl. J. Med. |volume=352 |issue=22 |pages=2271–84 |year=2005 |pmid=15930418 |doi=10.1056/NEJMoa051016|url=http://content.nejm.org/cgi/content/full/352/22/2271}}</ref>
A [[randomized controlled trial]] of a vaccine for adults aged at least 60 years reduced the incidence of zoster over three years from 3.3% to 1.6%; approximately 60 people would have to take the vaccine to prevent one case of shingles ([[number needed to treat]]=59).<ref name="pmid15930418">{{cite journal |author=Oxman MN, Levin MJ, Johnson GR, ''et al'' |title=A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults |journal=N. Engl. J. Med. |volume=352 |issue=22 |pages=2271–84 |year=2005 |pmid=15930418 |doi=10.1056/NEJMoa051016|url=http://content.nejm.org/cgi/content/full/352/22/2271}}</ref>


==References==
==References==

Revision as of 15:06, 22 October 2007

Prevention

The Centers for Disease Control recommends the zoster vaccination (Zostavax - which is different than the pediatric vaccine Variva) for adults aged at least 60 years:[1] Contraindications include:[2]

  • allergic to neomycin, or any component of the vaccine
  • immuncompromise due to radiation, corticosteroids, or conditions such as AIDS and cancers.
  • pregnancy
  • people who are in close contact with pregnant women who have not had chickenpox probably not have vaccine

A randomized controlled trial of a vaccine for adults aged at least 60 years reduced the incidence of zoster over three years from 3.3% to 1.6%; approximately 60 people would have to take the vaccine to prevent one case of shingles (number needed to treat=59).[3]

References

  1. Centers for Disease Control and Prevention (2006). CDC Media Relations Press Release - October 26, 2006. Retrieved on 2007-10-22.
  2. CBER - Zoster Vaccine, Live, (Oka/Merck), Zostavax Questions & Answers. Retrieved on 2007-10-22.
  3. Oxman MN, Levin MJ, Johnson GR, et al (2005). "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults". N. Engl. J. Med. 352 (22): 2271–84. DOI:10.1056/NEJMoa051016. PMID 15930418. Research Blogging.